ERBB2 and breast carcinoma: In the phase I clinical settings, AE37 plus GM-CSF immunotherapy appeared to be well-tolerated and safe, as well as capable of eliciting adjuvant-independent HER-2/neu-mediated immune reaction in disease-free, LN– breast cancer patients [206].